Sugi Predict

Sugi Predict / Compounds / SCHEMBL908565

SCHEMBL908565

SCHEMBL908565

COC(=O)Cc1ccccc1[N+](=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.58
▸ KMT2A Q03164 5/20 0.58
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ NPC1 O15118 2/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ ALDH1A1 P00352 5/20 0.57
▸ L3MBTL1 Q9Y468 2/20 0.57
▸ CYP2C19 P33261 2/20 0.56
▸ POLB P06746 1/20 0.56
▸ PTPN1 P18031 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ MAPT P10636 2/20 0.54
▸ PDGFRB P09619 1/20 0.54
▸ FGFR1 P11362 1/20 0.54
▸ PDGFRA P16234 1/20 0.54
▸ FLT1 P17948 1/20 0.54
▸ FGFR3 P22607 1/20 0.54
▸ KDR P35968 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29923859 1.00 MEN1 (0.58) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL9101688 0.86 MEN1 (0.52) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL31379000 0.86 ALDH1A1 (0.56) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL3291386 0.86 ALDH1A1 (0.56) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL10087451 0.86 PDGFRB (0.50) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL10267923 0.86 GPR35 (0.53) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL6543923 0.86 PDGFRB (0.50) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL18801901 0.85 LMNA (0.51) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL7633450 0.85 MEN1 (0.57) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL383289 0.85 ALDH1A1 (0.59) MEN1KMT2ASMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112724066-B Dihalogen impurity in ziprasidone hydrochloride intermediate and preparation method thereof 海南鑫开源医药科技有限公司 2022-10-21 — — CN claimed
CN-112724066-A Dihalogen impurity in ziprasidone hydrochloride intermediate and preparation method thereof 海南鑫开源医药科技有限公司 2021-04-30 — — CN claimed
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 — — WO disclosed
US-12552798-B2 Substituted imidazolecarboxamide as Bruton's tyrosine kinase inhibitors HENAN ZHIWEI BIOMEDICINE CO., LTD. (CN) 2026-02-17 — — US disclosed
US-20260027131-A1 PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS PRAESIDIA BIOTHERAPEUTICS INC (US) 2026-01-29 — — US disclosed
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2025-12-30 — — US disclosed
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS INC (US) 2025-11-27 — — US disclosed
EP-4594307-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2025-08-06 — — EP disclosed
US-20250154111-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-05-15 — — US disclosed
CN-119330836-A Preparation method of 2-substituted alkane aniline compound 帕潘纳(北京)科技有限公司 2025-01-21 — — CN disclosed
WO-2024073426-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed
US-6166040-A Indole compounds ELI LILLY AND COMPANY LIMITED (GB) 2000-12-26 — — US disclosed
EP-0963983-A1 Indol-2-ones as serotonin modulators ELI LILLY AND COMPANY LIMITED (GB) 1999-12-15 — — EP disclosed
WO-1999058525-A1 INDOLE DERIVATIVES AS 5-HT2A LIGANDS AND AS SEROTONINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY LIMITED (GB) 1999-11-18 — — WO disclosed
US-5652232-A VIRICIDES, TREATMENT OF RETROVIRUS INFECTIOUS DISEASE; AIDS SHIONOGI & CO., LTD. (JP) 1997-07-29 — — US disclosed
EP-0721945-A1 BENZOLACTAM DERIVATIVE SHIONOGI & CO., LTD. (JP) 1996-07-17 — — EP disclosed
US-5449682-A Angiotensin II antagonists incorporating a substituted benzyl element MERCK & CO., INC. (US) 1995-09-12 — — US disclosed
CN-1098722-A Tricyclic quinoxalinedione derivatives SUMITOMO PHARMA (JP) 1995-02-15 — — CN disclosed
US-5240938-A Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring MERCK & CO., INC. (US) 1993-08-31 — — US disclosed
US-4803197-A ANTIINFLAMMATORY AGENTS CIBA-GEIGY CORPORATION (US) 1989-02-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027131-A1 PRODRUGS, PRODRUG COMPOSITIONS AND RELATED METHODS DNPEP, SLC7A1, SLC6A7 MEN1 2907/4885KMT2A 2489/4885SMN1; SMN2 2965/4885
US-12509431-B2 1,4-dihydroquinazolinone compounds and uses thereof TNNT2, TNNI3, TNNC1 MEN1 3410/4885KMT2A 3822/4885SMN1; SMN2 1012/4885
US-12552798-B2 Substituted imidazolecarboxamide as Bruton's tyrosine kinase inhibitors BTK, LCK, SYK MEN1 2612/4885KMT2A 1154/4885SMN1; SMN2 3586/4885
US-20250154111-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, SDHA MEN1 2996/4885KMT2A 3454/4885SMN1; SMN2 1880/4885
US-20250361213-A1 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, SDHA MEN1 2996/4885KMT2A 3454/4885SMN1; SMN2 1880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.